Development of the M-SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands)

Sautner, Judith

doi:10.1093/rheumatology/keh360

Cited by 47 publications

(47 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These include the Health Assessment Questionnaire (HAQ),68 the Arthritis Hand Function Test (AHFT),69 the Arthritis Impact Measurement Scale 2 (AIMS2),70 the Cochin scale,71 the Score for Assessment and quantification of Chronic Rheumatic Affections of the Hands (SACRAH),67 72 the Functional Index for Osteoarthritis of the Hand (FIHOA)61 and the Australian/Canadian Osteoarthritis Hand Index (AUSCAN) 73. A systematic review of these instruments has been undertaken 74.…”

Section: Propositionmentioning

confidence: 99%

EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT

et al. 2008

View full text Add to dashboard Cite

Objectives: To develop evidence-based recommendations for the diagnosis of hand osteoarthritis (OA). Methods: The multidisciplinary guideline development group, representing 15 European countries, generated 10 key propositions regarding diagnosis using a Delphi consensus approach. For each recommendation, research evidence was searched for systematically. Whenever possible, the sensitivity, specificity and likelihood ratio (LR) were calculated; relative risk and odds ratios were estimated for risk factors for hand OA. Quality of evidence was categorised using the European League Against Rheumatism (EULAR) hierarchy, and strength of recommendation was assessed by the EULAR visual analogue scale. Results: Diagnostic topics included clinical manifestations, radiographic features, subgroups, differential diagnosis, laboratory tests, risk factors and comorbidities. The sensitivity, specificity and LR varied between tests depending upon the cut-off level, gold standard and controls. Overall, no single test could be used to define hand OA on its own (LR ,10) but a composite of the tests greatly increased the chance of the diagnosis. The probability of a subject having hand OA was 20% when Heberden nodes alone were present, but this increased to 88% when in addition the subject was over 40 years old, had a family history of nodes and had joint space narrowing in any finger joint. Conclusion: Ten key recommendations for diagnosis of hand OA were developed using research evidence and expert consensus. Diagnosis of hand OA should be based on assessment of a composite of features.

show abstract

Section: Propositionmentioning

confidence: 99%

EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT

et al. 2008

View full text Add to dashboard Cite

show abstract

“…It measures hand pain, stiffness and function [71]. The Modified Score for the Assessment and quantification of Rheumatoid Affections of the Hands (M-SAC-RAH), a shortened version of the SACRAH, is another self administered questionnaire assessing functional status, stiffness and pain in patients suffering with both hand osteoarthritis and rheumatoid arthritis [72]. It has been compared to the AUSCAN and demonstrated good correlation (r = 0.73, 0.75, 0.76 for pain, stiffness and function, P \ 0.001) [73].…”

Section: Quality Of Life Instrumentsmentioning

confidence: 99%

Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?

Din

Dodwell

Wakefield

et al. 2010

Breast Cancer Res Treat

View full text Add to dashboard Cite

Aromatase inhibitors (AIs) are a standard of care for the adjuvant treatment of hormone responsive early carcinoma of the breast as demonstrated in a number of large international phase III randomised trials. Arthralgia was a somewhat unexpected side effect of this class of agents and has proven to be potentially problematic in clinical practice. Although rates of up 35% have been reported in the randomised trials, the figure has been much higher in subsequent case series. There is concern that these symptoms are significant and may affect compliance and thus the overall efficacy of treatment. It is therefore extremely important that we evaluate this syndrome with a view to gaining more information regarding its clinical features and possible aetiological mechanism. The potential aetiological mechanisms and evidence for aromatase inhibitor-induced arthralgia (AIA) are reviewed in this article. Looking forward, it is now important that prospective clinical trials are well designed to evaluate this syndrome and potential therapeutic strategies to circumvent it. Radiological imaging and biochemical analyses may help our understanding of AIA and these are discussed.

show abstract

“…Fragebögen, die speziell für die Arthrose der Hand-und Fingergelenke entwickelt oder validiert wurden, sind der "Health Assessment Questionnaire" (HAQ) [20], der "AIMS-2" [33], der "AUSCAN" [6, 7], die "Cochin Skala" [16,17], der "Functional Index of HOA" (FIHOA) [14,15] und der "SACRAH" [31,37]. Zwischen diesen Fragebögen bestehen erhebliche inhaltliche Unterschiede [43].…”

Section: Alltagsfunktionunclassified

“…B. bei der chronischen Polyarthritis, als wichtig befunden wurde [17] und auch im ICF Core Set für Arthrose enthalten ist [13]. Sowohl im AUS-CAN-[6, 7] als auch im SACRAH- [31,37] Fragebogen ist eine Schmerz-Subskala enthalten, die im AUSCAN aus 5 und im SACRAH aus 4 Punkten besteht. Alle Punkte in beiden Fragebögen erfragen Schmerzen bei bestimmten Tätig-keiten oder im Ruhezustand im Gegensatz zur Schmerzmessung mittels VAS, bei der nach allgemeinem Schmerz unabhängig von einer Tätigkeit oder einem Aktivitätszustand gefragt wird.…”

Section: Schmerzunclassified

See 1 more Smart Citation

Klinische Ergebnismessgrößen bei Arthrose der Hand- und Fingergelenke aus der Perspektive der Patienten

et al. 2006

View full text Add to dashboard Cite

Osteoarthritis (OA) is the most common joint disease. While research activities in OA have concentrated on the knee and hip in recent years, knowledge and research results in the field of hand OA are still limited. In order to measure the effects of treatment or to obtain information on the course of a disease and the health status of a patient, outcome measures are commonly used in rheumatology. Such measures are variables which can be quantified and which represent either the perspective of health professionals or the perspective of patients or both. The aim of this article is to evaluate clinical outcome measures and corresponding instruments which are currently used for patients with hand OA, and to examine whether these measures and instruments represent the perspective of patients. For hand OA, measurements of disease activity and inflammation, function and performance, pain, mobility and stiffness, deformity and aesthetic damage are recommended by experts. Corresponding instruments are available for most of these outcome measures, but these often do not sufficiently represent the perspective of the patients. Some instruments lack reliability because standardized protocols for measurement have not yet been developed.

show abstract

Development of the M-SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands)

Abstract: M-SACRAH, the shortened and simplified version of the original SACRAH questionnaire, proved to be as reliable and as representative as SACRAH for hand status in individual HOA and RA patients.

Cited by 47 publications

References 12 publications

EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT

EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis: report of a task force of ESCISIT

Aromatase inhibitor-induced arthralgia in early breast cancer: what do we know and how can we find out more?

Klinische Ergebnismessgrößen bei Arthrose der Hand- und Fingergelenke aus der Perspektive der Patienten

Contact Info

Product

Resources

About